Navigation Links
Bard Kugel® Hernia Patch

ProductsBard Kugel® Hernia Patch
Company Davol, Inc.
Item Bard Kugel® Hernia Patch
Features 
  • Constructed of a double layer of monofilament polypropylene
  • Minimizes the possibility of a new hernia
  • Covers the entire inguinal floor, minimizing the chance of a recurrence or new hernia through all three potential sites: the indirect, direct and femoral
    • Description The Bard Kugel hernia patch in constructed of a double layer of monofilament polypropylene. This construction creates a positioning pocket, which is used to guide the patch into proper placement. The patch also contains a patent protected "memory recoil ring". This ring allows the patch to spring open and maintain its shape during placement. In addition to repairing the existing hernia, the Bard Kugel patch also minimizes the possibility of a new hernia. The prosthesis covers the entire inguinal floor, minimizing the chance of a recurrence or new hernia through all three potential sites: the indirect, direct and femoral. The result of the Bard Kugel hernia patch is an open, preperitoneal repair, which offers all the benefits of a laparoscopic hernia repair, without the possible complications and added costs.
    Info Davol, Inc.
    Customer Service: (800) 556-6756
    Web site: http://www.davol.com/

    Related medicine products :

    1. Surgisis® GOLD™ Hernia Repair Grafts
    2. Surgisis® IHM™ Inguinal Hernia Matrix
    3. PROLENE Hernia System
    4. Bard Composix Kugel Hernia Patch
    5. Self-Forming Hernia Mesh Plugs
    6. Surgisis EXL Hernia Repair Graft
    7. Neuro-Patch Synthetic Dura Substitute
    8. Ethisorb Dura Patch
    9. Webster Ref-Star with QwikPatch
    10. ProOptha Eye Patch
    11. GORE-TEX ACUSEAL Cardiovascular Patch
    Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 1Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 2Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 4Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 5Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 6Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 7Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 8Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 1Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 2